罗欣品牌怎么样 申请店铺

山东罗欣药业股份有限公司是由山东罗欣制药厂改制重组、罗欣医药集团有限公司控股、联合沈阳药科大学等共11家发起人共同设立的股份制公司，是严格按照现代企业制度和国家GMP要求组建的制药企业，被国家科技部认定为“国家重点高新技术企业”。公司建有粉针剂、冻干粉针剂、水针剂、固体制剂、化学原料药、头孢菌素类原料药等三十多条生产线，目前有十几个剂型、200多个产品规格上市，其中国家级新药41个，头孢类等各系列产品形成了从起始原料合成至制剂分装成品一条龙的生产规模。公司可年产粉针剂10亿支，冻干粉针剂3亿支，水针剂5亿支，片剂25亿片，胶囊剂20亿粒，颗粒剂3亿袋，干混悬剂8000万袋，头孢菌素类原料药300吨，其他化学原料药100吨。    

公司坚持“科技兴企”战略，积极和全国各大院校、科研机构合作，以沈阳药科大学等高等科研院所为科研后盾，并设立了“沈阳药科大学罗欣药业博士后流动工作站”、“沈阳药科大学罗欣药业教学培养基地”、“沈阳药科大学罗欣药业实习基地”、“沈阳药科大学罗欣药业毕业生就业基地”、“联合实验室”等。公司产品津欣等3个项目被列入国家“重大新药创制”科技重大专项，公司“盐酸头孢唑兰原料药及注射剂”等41个项目被列入山东省火炬计划、山东省科技发展计划、山东省技术创新项目。公司先后被认定为“国家综合性新药研发技术大平台（山东）产业化示范企业”、“中国专利山东明星企业”、“山东省创新型试点企业”，并建有国家认定企业技术中心、“泰山学者—药学特聘专家”岗位、山东省冻干粉针剂药物工程技术研究中心、山东省冻干粉针剂药物工程实验室、山东省冻干粉针剂药物重点实验室、山东省创新方法试点企业。2011年公司被工业和信息化部评为首届中国医药研发产品线最佳工业企业（第一名），经国家人力资源和社会保障部、全国博士后管理委员会审评，公司获准设立了国家博士后科研工作站，为公司培养、吸引和使用高层次专业技术人才，提升研发能力，促进创新体系建设提供了新的广阔的空间。

企业积极实施科技创造产品名牌，以名牌产品提高企业知名度，以企业知名度带动产品销售的策略，为企业发展奠定了坚实的后劲和基础。为加快科技创新的实施，公司加大了科技投入，每年从销售收入中提取5%作为科研经费，加快科技创新的实施，目前公司正加快实施的科研项目三十多个，临床验证项目二十多个，其中临床前和临床中实施的具有自主知识产权的一类新药有多个。公司注重科技人才队伍的培养和建设，现有专职科技人才206名，其中博士13名，硕士28名。

Shandong Luoxin Pharmaceutical Co., Ltd. is a joint-stock company established by 11 sponsors, including Shandong Luoxin pharmaceutical factory restructuring, Luoxin Pharmaceutical Group Co., Ltd. holding, and Shenyang Pharmaceutical University. It is a pharmaceutical enterprise established in strict accordance with modern enterprise system and national GMP requirements, and recognized as "national key high-tech enterprise" by the Ministry of science and technology of the people's Republic of China. The company has more than 30 production lines, including powder injection, freeze-dried powder injection, water injection, solid preparation, chemical API, cephalosporin API, etc. at present, there are more than a dozen dosage forms and more than 200 product specifications on the market, including 41 national level new drugs, cephalosporins and other series of products, which have formed a production scale from the synthesis of starting raw materials to the sub packaging of preparations. The company can produce 1 billion powder injections, 300 million freeze-dried powder injections, 500 million water injections, 2.5 billion tablets, 2 billion capsules, 300 million bags of granules, 80 million bags of dry suspension, 300 tons of cephalosporin APIs and 100 tons of other chemical APIs annually. The company adheres to the strategy of "invigorating the enterprise with science and technology", actively cooperates with major universities and scientific research institutions in China, and takes Shenyang Pharmaceutical University and other higher scientific research institutes as the scientific research backing. It has also set up "Luoxin pharmaceutical postdoctoral mobile workstation of Shenyang Pharmaceutical University", "Luoxin pharmaceutical teaching and training base of Shenyang Pharmaceutical University", "Luoxin pharmaceutical practice base of Shenyang Pharmaceutical University", "Shenyang Pharmaceutical Practice Base" Luoxin pharmaceutical graduate employment base and Joint Laboratory of Pharmaceutical University, etc. The company's three projects, including Jinxin, have been listed in the national major science and technology special project of "major new drug creation", and 41 projects, such as "cefazolin hydrochloride API and injection", have been listed in the torch plan of Shandong Province, the science and technology development plan of Shandong Province, and the technological innovation project of Shandong Province. The company has been successively recognized as the "national comprehensive new drug R & D technology platform (Shandong) industrialization demonstration enterprise", "China Patent Shandong Star Enterprise", "Shandong innovative pilot enterprise", and has established the national enterprise technology center, "Taishan scholar pharmaceutical expert" post, Shandong freeze dry powder injection drug Engineering Technology Research Center, Shandong freeze dry Powder injection drug Engineering Laboratory, Shandong freeze-dried powder injection drug key laboratory, Shandong innovation method pilot enterprise. In 2011, the company was rated as the best industrial enterprise (No.1) in the first Chinese pharmaceutical R & D product line by the Ministry of industry and information technology. After the review by the Ministry of human resources and social security and the National Postdoctoral Management Committee, the company was approved to set up a National Postdoctoral Research workstation to train, attract and use high-level professional and technical talents for the public, improve R & D capacity and promote innovation system Construction provides a new and broad space. Enterprises actively implement the strategy of science and technology to create famous brands, improve the popularity of enterprises with famous products, and promote the sales of products with the popularity of enterprises, which has laid a solid foundation for the development of enterprises. In order to speed up the implementation of scientific and technological innovation, the company has increased its investment in science and technology, taking 5% of the annual sales revenue as scientific research funds and accelerating the implementation of scientific and technological innovation. At present, the company is speeding up the implementation of more than 30 scientific research projects and more than 20 clinical verification projects, including more than one class of new drugs with independent intellectual property rights implemented before and in the clinic. The company attaches great importance to the cultivation and construction of scientific and technological talents, and now has 206 full-time scientific and technological talents, including 13 doctors and 28 masters.

本文链接： https://brand.waitui.com/c40a78d19.html 联系电话：05398241226